Clinical Trial

Twenty-year Follow-up of the Inter99 Cohort

Enrolling by Invitation
View on ClinicalTrials.gov →
Record status
This record was last updated February 28, 2024 (before its estimated September 1, 2024 completion). Its status may not reflect the trial's current state.
Summary
Being born small increases your risk of developing Type 2 diabetes (T2D) with age. Furthermore, data even suggest that some of the diseases ("complications") in the eyes, kidneys, nerves, liver, blood vessels and heart often seen in T2D patients may not only be due to high blood sugar levels, but rather they to some extent are due to reduced growth in your mother´s womb. The Inter99 cohort included 6784 Danish citizens aged 30 to 60 years when established 20 years ago. Data from the Inter99 cohort showed a strong role of low birth weight (LBW) on T2D risk. The aim is now to reexamine risk of T2D and complications in all the alive 6004 elderly Inter99 participants. Importantly, today there are available techniques to perform detailed examinations for even the earliest signs of complications in both subjects with and without diabetes, and the results of this study will altogether provide important new insights into both the origin and classification of T2D and associated complications. It is hypothesized that being born with lower birth weights increases the adult risk of T2D and heart disease and associated complications in the large and smaller blood vessels.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2021-12-20; most recent amendment 2024-02-26.
Status change: Recruiting → Enrolling by Invitation 2023-02-21
Trial Details
NCT Number NCT05166447
Lead Sponsor Bispebjerg Hospital
Collaborators: Steno Diabetes Center Copenhagen, The Novo Nordisk Foundation Center for Basic Metabolic Research, Rigshospitalet, Denmark
Conditions Coronary Heart Disease, Acute Myocardial Infarction, Cardiovascular Diseases, Type 2 Diabetes, Obesity, Birth Weight
Enrollment 4,000 participants
Start Date 2021-09-13
Primary Completion 2024-09-01 (estimated)
Study Completion 2028-12-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-28